Veeva Systems Sees AI as Growth Engine Beyond Its $6B 2030 Revenue Target

Veeva Systems NYSE: VEEV is positioning artificial intelligence as an incremental growth opportunity beyond its previously stated goal of reaching $6 billion in revenue by 2030, according to executives speaking at a Wells Fargo healthcare technology event. Paul Shawah, Veeva’s EVP of Commercial Strategy, said the company is continuing to build an industry cloud for life sciences that combines applications, data, agents and consulting across research and development and commercial operations. Its R&D offerings span clinical, quality, regulatory and safety functions, while its commercial portfolio includes CRM, content and data products. Shawah said Veeva’s more recent focus on AI represents a “major shift” for the company. Veeva’s AI strategy includes Veeva Vault AI , which embeds AI capabilities into its existing applications, and Veeva Falcon , an agentic AI layer intended to perform work within customer workflows. AI Seen as Incremental to 2030 Target Veeva’s $6 billion revenue target, issued about two years ago, was primarily based on its existing life-sciences enterprise applications, Shawah said. AI agents and Veeva’s expansion into horizontal markets were not major components of that outlook and are considered incremental opportunities. Veeva Systems: Increasing NDR and Other Wins Shawah said monetization will likely vary by AI offering and use case. Vault AI, which is designed to help users summarize information, make decisions and work more efficiently, will in most cases be monetized through consumption, such as token usage. Falcon, meanwhile, could be priced based on outcomes, including the number of documents processed or other business transactions. Veeva may also use enterprise license agreements for certain Falcon deployments, he said. “Our main focus” is maturing the products and establishing their value proposition, Shawah said, adding that the appropriate licensing model should follow from customer adoption. Gunnar Hansen, Veeva’s Head of Investor Relations, said the company is initially focused on getting AI products into customers’ hands and delivering value before determining longer-term revenue models. Executives cited regulatory communications as one potential Falcon use case. Shawah said drug regulators, including the U.S. Food and Drug Administration, may pause an approval process while seeking answers from a drugmaker. AI agents could help companies develop, translate and consistently deliver responses more quickly across geographies. Faster responses could shorten the time to approval, potentially allowing a product to reach patients and the market sooner.